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SARS-CoV-2 evolution during treatment of 
chronic infection
 
Steven A. Kemp1,19, Dami A. Collier1,2,3,19, Rawlings P. Datir2,3,19, Isabella A. T. M. Ferreira2,3, 
Salma Gayed4, Aminu Jahun5, Myra Hosmillo5, Chloe Rees-Spear1, Petra Mlcochova2,3, 
Ines Ushiro Lumb6, David J. Roberts6, Anita Chandra2,3, Nigel Temperton7, The CITIID-NIHR 
BioResource COVID-19 Collaboration*, The COVID-19 Genomics UK (COG-UK) Consortium*, 
Katherine Sharrocks4, Elizabeth Blane3, Yorgo Modis8, Kendra Leigh8, John Briggs8, 
Marit van Gils9, Kenneth G. C. Smith2,3, John R. Bradley3,10, Chris Smith11, Rainer Doffinger13, 
Lourdes Ceron-Gutierrez13, Gabriela Barcenas-Morales13,14, David D. Pollock15, 
Richard A. Goldstein1, Anna Smielewska5,11, Jordan P. Skittrall4,12,16, Theodore Gouliouris4, 
Ian G. Goodfellow5, Effrossyni Gkrania-Klotsas4, Christopher J. R. Illingworth12,17, 
Laura E. McCoy1 & Ravindra K. Gupta2,3,18 ✉
SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE21, and is 
a major antibody target. Here we report chronic SARS-CoV-2 with reduced sensitivity 
to neutralising antibodies in an immune suppressed individual treated with 
convalescent plasma, generating whole genome ultradeep sequences over 23 time 
points spanning 101 days. Little change was observed in the overall viral population 
structure following two courses of remdesivir over the first 57 days. However, 
following convalescent plasma therapy we observed large, dynamic virus population 
shifts, with the emergence of a dominant viral strain bearing D796H in S2 and ΔH69/
ΔV70 in the S1 N-terminal domain NTD of the Spike protein. As passively transferred 
serum antibodies diminished, viruses with the escape genotype diminished in 
frequency, before returning during a final, unsuccessful course of convalescent 
plasma. In vitro, the Spike escape double mutant bearing ΔH69/ΔV70 and D796H 
conferred modestly decreased sensitivity to convalescent plasma, whilst maintaining 
infectivity similar to wild type. D796H appeared to be the main contributor to 
decreased susceptibility but incurred an infectivity defect. The ΔH69/ΔV70 single 
mutant had two-fold higher infectivity compared to wild type, possibly compensating 
for the reduced infectivity of D796H. These data reveal strong selection on 
SARS-CoV-2 during convalescent plasma therapy associated with emergence of viral 
variants with evidence of reduced susceptibility to neutralising antibodies.
 
Clinical case history of SARS-CoV-2 infection in setting 
of immune-compromised host
A septuagenarian male was admitted to a tertiary hospital in summer 
of 2020 and had tested positive for SARS-CoV-2 RT-PCR 35 days previ-
ously on a nasopharyngeal swab (Day 1) at a local hospital (Extended 
data 1 and 2). His past medical history was significant for marginal B 
cell lymphoma diagnosed in 2012, with previous chemotherapy includ-
ing vincristine, prednisolone, cyclophosphamide and anti-CD20 B 
cell depletion with rituximab. It is likely that both chemotherapy and 
underlying lymphoma contributed to B and T cell combined immuno-
deficiency (Extended data 2 and 3, Supplementary Table 1). Computed 
tomography (CT) of the chest showed widespread abnormalities con-
sistent with COVID-19 pneumonia (Supplementary Figure 1). Treat-
ment included two 10-day courses of remdesivir with a five day gap 
in between (Extended data 1). Two units of convalescent plasma were 
administered on days 63 and 65 (Extended data 3). Following clinical 
deterioration, remdesivir and a unit of convalescent plasma were 
administered on day 95, but the individual unfortunately died on day 102 
(Supplementary text).
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Virus genomic comparative analysis of 23 sequential 
respiratory samples over 101 days
The majority of samples were respiratory samples from nose and throat 
or endotracheal aspirates during the period of intubation (Supplemen-
tary Table 3). Ct values ranged from 16-34 and all 23 respiratory samples 
were successfully sequenced by standard single molecule sequenc-
ing approach as per the ARTIC protocol implemented by COG-UK; of 
these 20 additionally underwent short-read deep sequencing using the 
Illumina platform (Supplementary table 4). There was general agree-
ment between the two methods (Extended data 4). However due to the 
higher reliability of Illumina for low frequency variants, this was used 
for formal analysis2,3. Additionally, single genome amplification and 
sequencing of Spike using extracted RNA from respiratory samples 
was used as an independent method to detect mutations observed 
(Extended data 4). Finally, we detected no evidence of recombination, 
based on two independent methods.
Maximum likelihood analysis of patient-derived whole genome con-
sensus sequences demonstrated clustering with other local sequences 
from the same region (Figure 1). The infecting strain was assigned to 
lineage 20B bearing the D614G Spike variant. Environmental sampling 
showed evidence of virus on surfaces such as telephone and call bell. 
Sequencing of these surface viruses showed clustering with those 
derived from the respiratory tract (Extended data 2). All samples were 
consistent with having arisen from a single underlying viral population. 
In our phylogenetic analysis, we included sequential sequences from 
three other local patients identified with persistent viral RNA shedding 
over a period of 4 weeks or more as well as two long term immunosup-
pressed SARS-CoV-2 ‘shedders’ recently reported4,5, (Extended data 2, 
Supplementary Table 2). While the sequences from the three local 
patients as well as from Avanzato et al5 showed little divergence with 
no amino acid changes in Spike over time, the case patient showed sig-
nificant diversification. The Choi et al report4 showed similar degree of 
diversification as the case patient. Further investigation of the sequence 
data suggested the existence of an underlying structure to the viral 
population in our patient, with samples collected at days 93 and 95 
being rooted within, but significantly divergent from the original 
population (Extended data 5 and 6). The relationship of the divergent 
samples to those at earlier time points argues against superinfection.
SARS-CoV-2 viral diversity
All samples tested positive by RT-PCR and there was no sustained change 
in Ct values throughout the 101 days following the first two courses of 
remdesivir (days 41 and 54), or the first two units of convalescent plasma 
with polyclonal antibodies (days 63 and 65, Extended data 3). Of note 
we were not able to culture virus from stored swab samples. Consen-
sus sequences from short read deep sequence Illumina data revealed 
dynamic population changes after day 65, as shown by a highlighter plot 
(Extended data 6). In addition, we were also able to follow the dynamics 
of virus populations down to low frequencies during the entire period 
(Figure 2, Supplementary Table 4). Following remdesivir at day 41 the 
low frequency variant analysis allowed us to observe transient amino 
acid changes in populations at below 50% abundance in Orf 1b, 3a and 
Spike, with a T39I (C27509T) mutation in ORF7a reaching 79% on day 
45 (Figure 2, pink, supplementary information). At day 66 we noted 
I513T in NSP2 (T2343C) and V157L (G13936T) in RdRp had emerged 
from undetectable at day 54 to almost 100% frequency (Figure 2, red 
and green dashed lines), with the polymerase being the more plausible 
candidate for driving this sweep. Notably, spike variant N501Y, which 
can increase the ACE2 receptor affinity6, and which is present in the 
new UK B1.1.7 lineage7, was observed on day 55 at 33% frequency, but 
was eliminated by the sweep of the NSP2/RdRp variant.
In contrast to the early period of infection, between days 66 and 82, 
following the first two administrations of convalescent sera, a shift 
in the virus population was observed, with a variant bearing D796H 
in S2 and ΔH69/ΔV70 in the S1 N-terminal domain (NTD) becoming 
the dominant population at day 82. This was identified in a nose 
and throat swab sample with high viral load as indicated by Ct of 23 
(Figure 3A). The deletion was detected transiently at baseline accord-
ing to short read deep sequencing. ΔH69/ΔV70 was due to an out of 
frame six nucleotide deletion resulting in the sequence of codon 68 
changing from ATA to ATC.
On Days 86 and 89, viruses obtained from upper respiratory tract 
samples were characterised by the Spike mutations Y200H and T240I, 
with the deletion/mutation pair observed on day 82 having fallen 
to frequencies of 10% or less (Figure 2 and 3). The Spike mutations 
Y200H and T240I were accompanied at high frequency by two other 
non-synonymous variants with similar allele frequencies, coding for 
I513T in NSP2, V157L in RdRp and N177S in NSP15 (Figure 2A). Both of 
these were also previously observed at >98% frequency in the sample 
on day 66 (Figure 2A, red and green lines), arguing that this new lineage 
emerged out of a previously existing population.
Sequencing of a nose and throat swab sample at day 93 identified 
viruses characterised by Spike mutations P330S at the edge of the RBD 
and W64G in S1 NTD at close to 100% abundance, with D796H along 
with ΔH69/ΔV70 at <1% abundance and the variants Y200H and T240I 
at frequencies of <2%. Viruses with the P330S variant were detected in 
two independent samples from different sampling sites, arguing against 
the possibility of contamination. The divergence of these samples from 
the remainder of the population (Figure 2, 3B and Extended data 5 
and 6) suggests the possibility that they represent a compartmentalised 
subpopulation.
Patterns in the variant frequencies suggest competition between 
virus populations carrying different mutations, viruses with the D796H/
ΔH69/ΔV70 deletion/mutation pair rising to high frequency during 
CP therapy, then being outcompeted by another population in the 
absence of therapy. Specifically, these data are consistent with a lineage 
of viruses with the NSP2 I513T and RdRp V157L variant, dominant on 
day 66, being outcompeted during therapy by the mutation/deletion 
variant. With the lapse in therapy, the original strain, having acquired 
NSP15 N1773S and the Spike mutations Y200H and T240I, regained 
dominance, followed by the emergence of a separate population with 
the W64G and P330S mutations.
In a final attempt to reduce the viral load, a third course of remdesivir 
(day 93) and third dose of CP (day 95) were administered. We observed a 
re-emergence of the D796H + ΔH69/ΔV70 viral population (Figure 2, 3). 
The inferred linkage of D796H and ΔH69/ΔV70 was maintained as evi-
denced by the highly similar frequencies of the two variants, suggest-
ing that the third unit of CP led to the re-emergence of this population 
under renewed positive selection. In further support of our proposed 
idea of competition, noted above, frequencies of these two variants 
appeared to mirror changes in the NSP2 I513T mutation (Figure 2), 
suggesting these as markers of opposing clades in the viral population. 
Ct values remained low throughout this period with hyperinflamma-
tion, eventually leading to multi-organ failure and death at day 102. 
The repeated increase in frequency of the viral population with CP 
therapy strongly supports the hypothesis that the deletion/mutation 
combination conferred selective advantage.
Spike mutants emerging post convalescent plasma 
impair neutralising antibody potency
Using lentiviral pseudotyping we generated wild type, ΔH69/ΔV70 + 
D796H and single mutant Spike proteins in enveloped virions in order 
to measure neutralisation activity of CP against these viruses (Figure 4). 
This system has been shown to give generally similar results to replica-
tion competent virus8,9. Spike protein from each mutant was detected 
in pelleted virions (Figure 4A). We also probed with an HIV-1 p24 anti-
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Supplementary Figure 2). We then measured infectivity of the pseu-
doviruses, correcting for virus input using reverse transcriptase activity 
measurement, and found that ΔH69/ΔV70 appeared to have two-fold 
higher infectivity over a single round of infection compared to wild 
type (Figure 4B, Extended data 7). By contrast, the D796H single mutant 
had significantly lower infectivity as compared to wild type and double 
mutant had similar infectivity to wild type (Figure 4B, Extended data 7).
We found that D796H alone and the D796H + ΔH69/ΔV70 double 
mutant were less sensitive to neutralisation by convalescent plasma 
samples (Figure 4C-E, Extended data 7). By contrast the ΔH69/ΔV70 
single mutant did not reduce neutralisation sensitivity. In addition, 
patient derived serum from days 64 and 66 (one day either side of CP2 
infusion) similarly showed lower potency against the D796H + ΔH69/
ΔV70 mutants (Figure 4F, G).
A panel of nineteen monoclonal antibodies (mAbs) isolated from 
three donors was previously identified to neutralize SARS-CoV-2. To 
establish if the mutations incurring in vivo (D796H and ΔH69/ΔV70) 
resulted in a global change in neutralization sensitivity we tested neu-
tralising mAbs targeting the seven major epitope clusters previously 
described (excluding non-neutralising clusters II, V and small [n =<2] 
neutralising clusters IV, X). The eight RBD-specific mAbs (Extended 
data 8) exhibited no major change in neutralisation potency and 
non-RBD specific COVA1-21 showing 3-5 fold reduction in potency 
against ΔH69/ΔV70+D796H and ΔH69/ΔV70, but not D796H alone9 
(Extended data 8). We observed no differences in neutralisation 
between single/double mutants and wild type, suggesting that the 
mechanism of escape was likely outside these epitopes in the RBD. 
These data confirm the specificity of the findings from convalescent 
plasma and suggest that mutations observed are related to antibodies 
targeting regions outside the RBD. Interestingly, ΔH69/ΔV70 containing 
viruses showed reduced neutralisation sensitivity to the mAb COVA1-21, 
targeting an as yet undefined epitope outside the RBD10.
To understand how the ΔH69/ΔV70 and D796H might confer anti-
body resistance, we assessed how they might affect the Spike structure 
(Extended data 9). We based this analysis primarily on a structure lack-
ing stabilising modifications (PDB 6xr8)11, but also referred to stabilised 
structures determined at different pH values12. ΔH69/ΔV70 is located 
in a disordered, glycosylated loop at the distal surface of the NTD, near 
the binding site of polyclonal antibodies derived from COV57 plasma13,14 
(Extended data 9). As this loop is flexible and highly accessible, ΔH69/
V70 could in principle affect antibody binding in this region. D796 is 
located near the base of Spike, in a surface loop that is structurally 
somewhat disordered in the prefusion conformation and becomes part 
of a large disordered region in the post fusion S2 trimer11 (Extended 
data 9). The loop containing residue 796 is proposed to be targeted by 
antibodies15, despite mutations at position 796 being relatively uncom-
mon (Extended data 9). In the RBD-down Spike structures11,12, D796 
forms contacts with residues in the neighbouring protomer, including 
the glycosylated residue N709 (Extended data 9).
Discussion
Here we have documented a repeated evolutionary response by 
SARS-CoV-2 in the presence of antibody therapy during the course of 
a persistent infection in an immunocompromised host. The observa-
tion of potential selection for specific variants coinciding with the 
presence of antibodies from convalescent plasma is supported by 
the experimental finding of two-fold reduced susceptibility of these 
viruses to convalescent plasma containing polyclonal antibodies. In 
this case the emergence of the variant was not the primary reason for 
treatment failure.
We have noted in our analysis signs of compartmentalised viral rep-
lication based on the sequences recovered in upper respiratory tract 
samples. Both population genetic and small animal studies have shown 
a lack of reassortment between influenza viruses within a single host 
during an infection, suggesting that acute respiratory viral infection 
may be characterised by spatially distinct viral populations16,17. In the 
analysis of data, it is important to distinguish genetic changes which 
occur in the primary viral population from apparent changes that arise 
from the stochastic observation of spatially distinct subpopulations in 
the host. While the samples we observe on days 93 and 95 of infection 
are genetically distinct from the others, the remaining samples are 
consistent with arising from a consistent viral population. We note 
that Choi et al reported the detection in post-mortem tissue of viral 
RNA not only in lung tissue, but also in the spleen, liver, and heart4. 
Mixing of virus from different compartments, for example via blood, 
or movement of secretions from lower to upper respiratory tract, could 
lead to fluctuations in viral populations at particular sampling sites.
This is a single case report and therefore limited conclusions can be 
drawn about generalisability.
An important limitation is that the data were derived from sampling 
from the upper respiratory tract and not the lower tract, thus limiting 
the inferences that can be drawn regarding viral populations in this 
single case.
In addition to documenting the emergence of SARS-CoV-2 Spike 
ΔH69/ΔV70 in vivo, we show that this mutation modestly increases 
infectivity of the Spike protein in a pseudotyping assay. The deletion 
was observed contemporaneously with the rare S2 mutation D796H 
after two separate courses of CP, with other viral populations emerging. 
D796H, but not ΔH69/ΔV70, conferred reduction in susceptibility to 
polyclonal antibodies in the units of CP administered, though we cannot 
speculate as to their individual impacts on sera from other individuals. 
It is intriguing that the ΔH69/ΔV70 + D796H double mutant diminished 
in between CP courses, suggesting that there were other selective forces 
at play in the intervening period, possibly driven by the inflammation 
observed in the individual. This includes the possibility that the hap-
lotype with ΔH69/ΔV70 + D796H may have carried mutations in other 
regions deleterious during that intervening period. Although ΔH69/
V70 is expanding at a high rate18, D796 mutations are also increasing. 
D796H has been documented in 0.02% of global sequences and D796Y 
appears in 0.05% of global sequences (Extended data 9).
The effects of CP on virus evolution seen here are unlikely to apply 
in immune competent hosts where viral diversity is likely to be lower 
due to better immune control. Our data highlight that infection control 
measures may need to be tailored to the needs of immunocompro-
mised patients and also caution in interpretation of CDC guidelines 
that recommend 20 days as the upper limit of infection prevention 
precautions in immune compromised patients who are afebrile19. Due 
to the difficulty with culturing clinical isolates, use of surrogates are 
warranted20. However, where detection of ongoing viral evolution is 
possible, this serves as a clear proxy for the existence of infectious virus. 
In our case we detected environmental contamination whilst in a single 
occupancy room and the patient was moved to a negative-pressure 
high air-change infectious disease isolation room.
Clinical efficacy of convalescent plasma in severe COVID-19 has not 
been demonstrated21, and its use in different stages of infection and 
disease remains experimental; as such, we suggest that it should be 
reserved for use within clinical trials, with rigorous monitoring of clini-
cal and virological parameters. The data from this single case report 
might warrant caution in use of convalescent plasma in patients with 
immune suppression of both T cell and B cell arms; in such cases, the 
antibodies administered have little support from cytotoxic T cells, 
thereby reducing chances of clearance and theoretically raising the 
potential for escape mutations. Whilst we await further data, where 
clinical trial enrolment is not possible, convalescent plasma adminis-
tered for clinical need in immune suppression should ideally only be 
considered as part of observational studies, undertaken preferably 
in single occupancy rooms with enhanced infection control precau-
tions, including SARS-CoV-2 environmental sampling and real-time 
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of viral evolution in response to different selection pressures in the 
immunocompromised host is necessary not only for improved patient 
management but also for public health benefit.
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Fig. 1 | Analysis of 23 Patient derived whole SARS-CoV-2 genome sequences. 
in context of local sequences and other cases of chronic SARS-CoV-2 shedding. 
Circularised maximum-likelihood phylogenetic tree rooted on the Wuhan-Hu-1 
reference sequence, showing a subset of 250 local SARS-CoV-2 genomes from 
GISAID. This diagram highlights significant diversity of the case patient 
(green) compared to three other local patients with prolonged shedding  
(blue, red and purple sequences). All “United Kingdom / English” SARS-CoV-2 
genomes were downloaded from the GISAID database and a random subset of 
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Fig. 2 | Whole genome variant trajectories showing amino acids and 
relationship to treatments. Data based on Illumina short read ultra deep 
sequencing at 1000x coverage. Variants shown reached a frequency of at least 
10% in at least 2 samples. Treatments indicated are convalescent plasma (CP) 
and Remdesivir (RDV). Variants described in the text are designated by labels 
using the same colouring as the position in the genome. Variants labelled are 
represented by dashed lines. A. Variants detected in the patient from days 1-82. 
*D796H (light blue) is at the same frequency as NSP3 K902N (orange) therefore 
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Fig. 3 | Longitudinal variant frequencies and phylogenetic relationships 
for virus populations bearing six Spike (S) mutations A. At baseline, all six S 
variants (Illumina sequencing) except for ΔH69/V70 were absent (<1% and <20 
reads). Approximately two weeks after receiving two units of convalescent 
plasma (CP), viral populations carrying ΔH69/V70 and D796H mutants rose to 
frequencies >80% but decreased significantly four days later. This population 
was replaced by a population bearing Y200H and T240I, detected in two 
samples over a period of 6 days. These viral populations were then replaced by 
virus carrying W64G and P330S mutations in Spike, which both dominated at 
day 93. Following a 3rd course of remdesivir and an additional unit of 
convalescent plasma, the ΔH69/V70 and D796H virus population re-emerged 
to become the dominant viral strain reaching variant frequencies of >75%. Pairs 
of mutations arose and disappeared simultaneously indicating linkage on the 
same viral haplotype. CT values from respiratory samples are indicated on the 
right y-axis (black dashed line and triangles). Where there were duplicate 
readings on the same day, to remain consistent, N+T samples were plotted B. 
Maximum likelihood phylogenetic tree of the case patient with day of sampling 
indicated. Spike mutations defining each of the clades are shown ancestrally on 
the branches on which they arose. On dates where multiple samples were 
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Fig. 4 | Spike mutant D796H + ΔH69/V70 infectivity and sensitivity 
convalescent plasma (CP). A. western blot of virus pellets after centrifugation of 
supernatants from cells transfected with lentiviral pseudotyping plasmids 
including Spike protein. Blots are representative of two independent 
transfections. B. Single round Infectivity of luciferase expressing lentivirus 
pseudotyped with SARS-CoV-2 Spike protein (WT versus mutant) on 293T cells 
co-transfected with ACE2 and TMPRSS2 plasmids. Infectivity is corrected for 
reverse transcriptase activity in virus supernatant as measured by real time PCR. 
Data points represent technical replicates (n=3) with mean and error bars 
representing standard error of mean; data are representative of two independent 
experiments C-E. convalescent plasma (CP units 1-3) neutralization potency 
against pseudovirus virus bearing Spike mutants D796H, ΔH69/V70 and D796H + 
ΔH69/V70 F, G patient serum neutralisation potency against pseudovirus virus 
bearing Spike mutants D796H, ΔH69/V70 and D796H + ΔH69/V70. Patient serum 
was taken at indicated Day (D). Indicated is serum dilution required to inhibit 50% 
of virus infection (ID50), expressed as fold change relative to WT. Data points 
represent means of technical replicates and each data point is an independent 





























Clinical Sample Collection and Next generation sequencing
Serial samples were collected from the patient periodically from the 
lower respiratory tract (sputum or endotracheal aspirate), upper res-
piratory tract (throat and nasal swab), and from stool. Nucleic acid 
extraction was done from 500µl of sample with a dilution of MS2 
bacteriophage to act as an internal control, using the easyMAG plat-
form (Biomerieux, Marcy-l'Étoile) according to the manufacturers’ 
instructions. All samples were tested for presence of SARS-CoV-2 with 
a validated one-step RT q-PCR assay developed in conjunction with the 
Public Health England Clinical Microbiology22. Amplification reaction 
were all performed on a Rotorgene™ PCR instrument. Samples which 
generated a CT of ≤36 were considered to be positive.
Sera from recovered patients in the COVIDx study23 were used for 
testing of neutralisation activity by SARS-CoV-2 mutants.
SARS-CoV-2 serology by multiplex particle-based flow 
cytometry (Luminex)
Recombinant SARS-CoV-2 N, S and RBD were covalently coupled to 
distinct carboxylated bead sets (Luminex; Netherlands) to form a 3-plex 
and analyzed as previously described (Xiong et al. 2020). Specific bind-
ing was reported as mean fluorescence intensities (MFI).
Whole blood T cell and innate stimulation assay
Whole blood was diluted 1:5 in RPMI into 96-well F plates (Corning) 
and activated by single stimulation with phytohemagglutinin (PHA; 
10 µg/ml; Sigma-Aldrich), or LPS (1 µg/ml, List Biochemicals) or by 
co-stimulating with anti-CD3 (MEM57, Abcam, 200 ng/ml, 1:1000) 
and IL-2 (Immunotools, 1430U/ml, 1:1000). Supernatants were taken 
after 24 hours. Levels (pg/ml) are shown for IFNg, IL17, IL2, TNFa, IL6, 
IL1b and IL10. Cytokines were measured by multiplexed particle based 
Flow cytometry on a Luminex analyzer (Bio-Plex, Bio-Rad, UK) using 
an R&D Systems custom kit (R&D Systems, UK).
For viral genomic sequencing, total RNA was extracted from samples 
as described. Samples were sequenced using MinION flow cells version 
9.4.1 (Oxford Nanopore Technologies) following the ARTICnetwork V3 
protocol (https://doi.org/10.17504/protocols.io.bbmuik6w) and BAM 
files assembled using the ARTICnetwork assembly pipeline (https://
artic.network/ncov-2019/ncov2019-bioinformatics-sop.html). A rep-
resentative set of 10 sequences were selected and also sequenced using 
the Illumina MiSeq platform. Amplicons were diluted to 2 ng/µl and 25 µl 
(50 ng) were used as input for each library preparation reaction. The 
library preparation used KAPA Hyper Prep kit (Roche) according to 
manufacturer’s instructions. Briefly, amplicons were end-repaired and 
had A-overhang added; these were then ligated with 15mM of NEXTflex 
DNA Barcodes (Bio Scientific, Texas, USA). Post-ligation products were 
cleaned using AMPure beads and eluted in 25 µl. Then, 20 µl were used 
for library amplification by 5 cycles of PCR. For the negative controls, 
1ng was used for ligation-based library preparation. All libraries were 
assayed using TapeStation (Agilent Technologies, California, USA) to 
assess fragment size and quantified by QPCR. All libraries were then 
pooled in equimolar accordingly. Libraries were loaded at 15nM and 
spiked in 5% PhiX (Illumina, California, USA) and sequenced on one 
MiSeq 500 cycle using a Miseq Nano v2 with 2x 250 paired-end sequenc-
ing. A minimum of ten reads were required for a variant call.
Bioinformatics Processes
For long-read sequencing, genomes were assembled with 
reference-based assembly and a curated bioinformatics pipeline with 
20x minimum coverage across the whole-genome24. For short-read 
sequencing, FASTQs were downloaded, poor-quality reads were identi-
fied and removed, and both Illumina and PHiX adapters were removed 
using TrimGalore v0.6.625. Trimmed paired-end reads were mapped 
to the National Center for Biotechnology Information SARS-CoV-2 
reference sequence MN908947.3 using MiniMap2-2.17 with arguments 
-ax and sr26. BAM files were then sorted and indexed with samtools v1.11 
and PCR optical duplicates removed using Picard (http://broadinstitute. 
github.io/picard). A consensus sequences of nucleic acids with a 
minimum whole-genome coverage of at least 20× were generated with 
BCFtools using a 0% majority threshold.
Variant calling
Variant frequencies were validated using custom code as part of 
the AnCovMulti package (github.com/PollockLaboratory/AnCovMulti). 
The main idea behind this validation was to identify and remove con-
sistent potential amplification errors and mutability near the end of 
Illumina reads. Furthermore, stringent filtering was applied to remove 
biased amplification of early laboratory-induced mutations or very 
low copy variations.
Filtering consisted of requiring exact initiation at a primer within 
two bp of the start of a read, a minimum of 247 bp length read, fewer 
than four well-separated sites divergent from the reference sequence, 
a maximum insertion size of three nucleotides, a maximum deletion 
size of 11 bp, and resolution of conflicting signal from different primers.
Single Genome Amplification and sequencing
Viral RNA extracts were reverse transcribed from each sample to suffi-
ciently capture the diversity of the viral population without introducing 
resampling bias. SuperScript IV (Thermofisher Scientific) and the gene 
specific primers were used for reverse transcription. Template RNA was 
degraded with RNAse H (Thermofisher Scientific). All primers used 
were ‘in-house’ primers designed using the multiple sequence align-
ment of the patient’s consensus NGS sequences. Partial Spike (amino 
acids 21- 800) was amplified as 1 continuous length of DNA (Spike ~ 1.8 
kb) by nested PCR. Terminally diluted cDNA was PCR- amplified using 
Platinum® Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA) 
so that 30% of reactions were positive27. By Poisson statistics, sequences 
were deemed ≥80% likely to be derived from HIV-1 single genomes. We 
obtained between 20–60 single genomes at each sample time point to 
achieve 90% confidence of detecting variants present at ≥8% of the viral 
population in vivo28,29. Partial spike amplicons obtained from terminal 
dilution PCR amplification were Sanger sequenced to form a contiguous 
sequence using another set of 8 in-house primers. Sanger sequencing 
was provided by Genewiz UK and manual sequence editing was per-
formed using DNA Dynamo software (Blue Tractor Software Ltd, UK).
Phylogenetic Analysis
All available full-genome SARS-CoV-2 sequences were downloaded from 
the GISAID database (http://gisaid.org/)30 on 16th December. Duplicate 
and low-quality sequences (>5% N regions) were removed, leaving a 
dataset of 212,297 sequences with a length of >29,000bp. All sequences 
were sorted by name and only sequences sequenced with United King-
dom / England identifiers were retained. From this dataset, sequences 
were de-duplicated and where background sequences were required 
in figures, randomly subsampled using seqtk (https://github.com/lh3/
seqtk). All sequences were aligned to the SARS-CoV-2 reference strain 
MN908947.3, using MAFFT v7.475 with automatic flavour selection31. 
Major SARS-CoV-2 clade memberships were assigned to all sequences 
using both the Nextclade server v0.9 (https://clades.nextstrain.org/) 
and Phylogenetic Assignment Of Named Global Outbreak Lineages 
(pangolin)32.
Maximum likelihood phylogenetic trees were produced using the 
above curated dataset using IQ-TREE v2.1.233. Evolutionary model 
selection for trees were inferred using ModelFinder34 and trees were 
estimated using the GTR+F+I model with 1000 ultrafast bootstrap 
replicates35. All trees were visualised with Figtree v.1.4.4 (http://tree.
bio.ed.ac.uk/software/figtree/), rooted on the SARS-CoV-2 reference 
sequence and nodes arranged in descending order. Nodes with boot-



























In-depth allele frequency variant calling
The SAMFIRE package version 1.0636 was used to call allele frequency 
trajectories from BAM file data. Reads were included in this analysis 
if they had a median PHRED score of at least 30, trimming the ends 
of reads to achieve this if necessary. Nucleotides were then filtered 
to have a PHRED score of at least 30; reads with fewer than 30 such 
reads were discarded. Distances between sequences, accounting for 
low-frequency variant information, was also conducted using SAMFIRE. 
The sequence distance metric, described in an earlier paper37, combines 
allele frequencies across the whole genome. Where L is the length of 
the genome, we define q(t) as a 4 x L element vector describing the 
frequencies of each of the nucleotides A, C, G, and T at each locus in 
the viral genome sampled at time t. For any given locus i in the genome 
we calculate the change in allele frequencies between the times t1 and 
t2 via a generalisation of the Hamming distance 
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where the vertical lines indicate the absolute value of the difference. 
These statistics were then combined across the genome to generate 
the pairwise sequence distance metric
q q ∑D t t d q t q t( ( ), ( )) = ( ( ), ( ))
i
i i1 2 1 2
The Mathematica software package was to conduct a regression analy-
sis of pairwise sequence distances against time, leading to an estimate 
of a mean rate of within-host sequence evolution. In contrast to the 
phylogenetic analysis, this approach assumed the samples collected on 
days 93 and 95 to arise via stochastic emission from a spatially separated 
subpopulation within the host, leading to a lower inferred rate of viral 
evolution for the bulk of the viral population.
All variants were indecently validated using custom code as part of the 
AnCovMulti package, found at https://github.com/PollockLaboratory/ 
AnCovMulti.
Western blot analysis
Forty-eight hours after transfection of cells with plasmid prepara-
tions, the culture supernatant was harvested and passed through a 
0.45-µm-pore-size filter to remove cellular debris. The filtrate was 
centrifuged at 15,000 rpm for 120 min to pellet virions. The pelleted 
virions were lysed in Laemmli reducing buffer (1 M Tris-HCl [pH 6.8], 
SDS, 100% glycerol, β-mercaptoethanol, and bromophenol blue). Pel-
leted virions were subjected to electrophoresis on SDS–4 to 12% bis-Tris 
protein gels (Thermo Fisher Scientific) under reducing conditions. 
This was followed by electroblotting onto polyvinylidene difluoride 
(PVDF) membranes. The SARS-CoV-2 Spike proteins were visualized by a 
ChemiDoc® MP imaging system (Biorad) using anti-Spike S2 (Invitrogen 
at 1:1000 dilution) and anti-p24 Gag antibodies (NIH AIDS Reagents 
1:1000 dilution).
Recombination Detection
All sequences were tested for potential recombination, as this would 
impact on evolutionary estimates. Potential recombination events 
were explored with nine algorithms (RDP, MaxChi, SisScan, GeneConv, 
Bootscan, PhylPro, Chimera, LARD and 3SEQ), implemented in RDP5 
with default settings38. To corroborate any findings, ClonalFrameML 
v1.1239 was also used to infer recombination breakpoints. Neither 
programs indicated evidence of recombination in our data.
Structural Viewing
The Pymol Molecular Graphics System v2.4.0 (https://github.com/
schrodinger/pymol-open-source/releases) was used to map the 
location of the four spike mutations of interested onto a SARS-CoV-2 
spike structure visualised by Wrobel et al (PDB: 6ZGE)40.
Testing of convalescent plasma for antibody titres
The Anti-SARS-CoV-2 ELISA (IgG) assay used to test CP for antibody 
titres was Euroimmun Medizinische Labordiagnostika AG. This indirect 
ELISA based assay uses a recombinant structural spike 1 (S1) protein of 
SARS-CoV-2 expressed in the human cell line HEK 293 for the detection 
of SARS-CoV2 IgG.
Generation of Spike mutants
Amino acid substitutions were introduced into the D614G pCDNA_
SARS-CoV-2_Spike plasmid as previously described41 using the 
QuikChange Lightening Site-Directed Mutagenesis kit, following the 
manufacturer’s instructions (Agilent Technologies, Inc., Santa Clara, CA).
Pseudotype virus preparation
Viral vectors were prepared by transfection of 293T cells by using 
Fugene HD transfection reagent (Promega). 293T cells were transfected 
with a mixture of 11ul of Fugene HD, 1µg of pCDNAΔ19Spike-HA, 1ug 
of p8.91 HIV-1 gag-pol expression vector42,43, and 1.5µg of pCSFLW 
(expressing the firefly luciferase reporter gene with the HIV-1 packag-
ing signal). Viral supernatant was collected at 48 and 72h after trans-
fection, filtered through 0.45um filter and stored at -80˚C. The 50% 
tissue culture infectious dose (TCID50) of SARS-CoV-2 pseudovirus 
was determined using Steady-Glo Luciferase assay system (Promega).
Standardisation of virus input by SYBR Green-based product- 
enhanced PCR assay (SG-PERT)
The reverse transcriptase activity of virus preparations was deter-
mined by qPCR using a SYBR Green-based product-enhanced PCR 
assay (SG-PERT) as previously described44. Briefly, 10-fold dilutions of 
virus supernatant were lysed in a 1:1 ratio in a 2x lysis solution (made up 
of 40% glycerol v/v 0.25% Trition X-100 v/v 100mM KCl, RNase inhibitor 
0.8 U/ml, TrisHCL 100mM, buffered to pH7.4) for 10 minutes at room 
temperature.
12µl of each sample lysate was added to thirteen 13µl of a SYBR 
Green master mix (containing 0.5µM of MS2-RNA Fwd and Rev prim-
ers, 3.5pmol/ml of MS2-RNA, and 0.125U/µl of Ribolock RNAse inhibitor 
and cycled in a QuantStudio. Relative amounts of reverse transcriptase 
activity were determined as the rate of transcription of bacteriophage 
MS2 RNA, with absolute RT activity calculated by comparing the relative 
amounts of RT to an RT standard of known activity.
Serum/plasma pseudotype neutralization assay
Spike pseudotype assays have been shown to have similar charac-
teristics as neutralisation testing using fully infectious wild type 
SARS-CoV-28.Virus neutralisation assays were performed on 293T cell 
transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-2 
Spike pseudotyped virus expressing luciferase45. Pseudotyped virus 
was incubated with serial dilution of heat inactivated human serum 
samples or convalescent plasma in duplicate for 1h at 37˚C. Virus and 
cell only controls were also included. Then, freshly trypsinized 293T 
ACE2/TMPRSS2 expressing cells were added to each well. Following 
48h incubation in a 5% CO2 environment at 37 °C, the luminescence 
was measured using Steady-Glo Luciferase assay system (Promega).
mAb pseudotype neutralisation assay
Virus neutralisation assays were performed on HeLa cells stably express-
ing ACE2 and using SARS-CoV-2 Spike pseudotyped virus expressing 
luciferase as previously described46. Pseudotyped virus was incubated 
with serial dilution of purified mAbs9 in duplicate for 1h at 37˚C. Then, 
freshly trypsinized HeLa ACE2- expressing cells were added to each 
well. Following 48h incubation in a 5% CO2 environment at 37 °C, the 




























(Promega) and neutralization calculated relative to virus only controls. 
IC50 values were calculated in GraphPad Prism.
Ethics
The study was approved by the East of England – Cambridge Central 
Research Ethics Committee (17/EE/0025). Written informed consent 
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under ethics review board (17/EE/0025).
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
Long-read sequencing data that support the findings of this study have 
been deposited in the NCBI SRA database with the accession codes 
SAMN16976824 - SAMN16976846 under BioProject PRJNA682013. Short 
reads and data used to construct figures were deposited at https://
github.com/Steven-Kemp/sequence_files. All data are also available 
from the corresponding author. Source data are provided with this 
paper.
Code availability
The SAMFIRE package Version 1.06 was used for filtering and calling 
variants from the Illumina data. It is available at https://github.com/cjri/
samfire/ for review. Additional code was used to validate the variant fre-
quencies and can be found at https://github.com/PollockLaboratory/ 
AnCovMulti .
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Extended Data Fig. 2 | A. Blood parameters over time in patient case. : White 
cell count (WCC) and lymphocyte counts are expressed as x103 Cells/mm3. CRP: 
C reactive protein. B. Assessment of T cell and innate function. Whole blood 
cytokines were measured in whole blood after 24 hours stimulation either after 
T-cell stimulation with PHA or anti CD3/IL2 or innate stimulation with LPS. 
Healthy controls are shown as grey circles (N=15), Patient at d71 and d98 is 
shown as blue circles or red circles respectively. Cytokine levels are shown as 



























Extended Data Fig. 3 | A. Serum SARS-CoV-2 antibody levels and virus 
population changes in chronic SARS-CoV-2 infection. Anti SARS-CoV2 IgG 
antibodies in patient and pre/post convalescent plasma compared to RNA+ 
Covid19 patients and prepandemic healthy controls: Red, grey and gold. : 
IgG antibodies to SARS-CoV2 nucleocapsid protein (N), trimeric S protein (S) 
and the receptor binding domain (RBD) were measured by multiplexed particle 
based flow cytometry (Luminex) in RNA+ COVID-19 patients (N=20, red dots), 
Pre-pandemic healthy controls (N=20, grey dots) and in the convalescent 
donor plasma (orange dots); Results are shown as mean fluorescent intensity 
(MFI) +/- SD. Patient sera over time in blue: Anti SARS-CoV2 IgG to N (blue 
squares), S (blue circles) and RBD (blue triangles). Timing of CP units is also 
shown. B. SARS-CoV-2 antibody titres in patient and in convalescent 
plasma. Measurement of SARS-CoV-2 specific IgG antibody titres in three units 




























Extended Data Fig. 4 | Comparison between short-read (Illumina) and 
long-read single molecule (Oxford Nanopore) sequencing methods for the 
six observed Spike mutations. Concordance was generally good between the 
majority of timepoints, however due to large discrepancies in a number of 
timepoints, we suggest that due to the high base calling error rate, Nanopore is 
not yet suitable for calling minority variants. As such, all figures in the main 
paper were produced using Illumina data only. B. Single genome sequencing 
(SGS) data from respiratory samples at indicated days. Indicated are the 
number of single genomes obtained at each time point with the mutations of 
interest (identified by deep sequencing). *denominator is 19 as for 2 samples 
the primer reads were poor quality at amino acid 796 at day 98. Amino acid 
variant and corresponding nucleotide position: S:W64G = 21752, S: Δ69 = 21765-



























Extended Data Fig. 5 | Evidence for within-host cladal structure. A. Pairwise 
distances between samples measured using the all-locus distance metric 
plotted against pairwise distances in time (measured in days) between samples 
being collected. Internal distances between samples in the proposed main 
clade are shown in black, distances between samples in the main clade and 
samples collected on days 93 and 95 are shown in red, and internal distances 
between samples collected on days 93 and 95 are shown in green. B. Pairwise 
distances between samples in the larger clade (black) and between these 
samples and those collected on days 93 and 95 (red). The median values of the 
distributions of these values are significantly different according to a Mann 
Whitney test. C. Pairwise distances between samples in the main clade, once 
those collected on days 86, 89, 93, 95 have been removed (black) and between 
these samples and those collected on days 86 and 89 (red). The median values 
of the distributions of these values are not significantly different at the 5 level 























































Extended Data Fig. 6 | A. Close-view maximum-likelihood phylogenetic 
tree. indicating the diversity of the case patient and three other long-term 
shedders from the local area (red, blue and purple), compared to recently 
published sequences from Choi et al (orange) and Avanzato et al (gold). Control 
patients generally showed limited diversity temporally, though the Choi et al 
sequences were highly divergent. Environmental samples (patient’s call bell, 
and patient’s mobile phone) are indicated. Tree branched have been collapsed 
where bootstrap support was <60. B. Highlighter plot indicating nucleotide 
changes at consensus level in sequential respiratory samples compared to 
the consensus sequence at first diagnosis of COVID-19. Each row indicates 
the timepoint the sample was collected (number of days from first positive 
SARS-CoV-2 RT-PCR). Black dashed lines indicate the RNA-dependent RNA 
polymerase (RdRp) and Spike regions of the genome. There were few 
nucleotide substitutions between days 1-54, despite the patient receiving two 
courses of remdesivir. The first major changes in the spike genome occurred on 
day 82, following convalescent plasma given on days 63 and 65. The amino acid 
deletion in S1, ΔH69/V70 is indicated by the black lines. Sites: Endotracheal 




























Extended Data Fig. 7 | In vitro infectivity and neutralisation sensitivity of 
Spike pseudotyped lentiviruses. A. infection of target 293T cells expressing 
TMPRSS2 and ACE2 receptors using equal amounts of virus as determined by 
reverse transcriptase activity. Data points represent technical replicates (n=2), 
with mean shown with error bars representing standard deviation. Data are 
representative of n=2 independent experiments (n=2). B. Representative 
Inverse dilution plots for Spike variants against convalescent plasma units 1-3. 
Data points represent mean neutralisation of technical replicates and error 
bars represent standard error of the mean of replicates. Data are 



























Extended Data Fig. 8 | A. Neutralization potency of a panel of monoclonal 
antibodies targeting the RBD is not impacted by Spike mutations D796H or 
ΔH69/V70. Lentivirus pseudotyped with SARS-CoV-2 Spike protein: WT 
(D614G background), D796H, ΔH69/V70, D796H+ΔH69/V70 were produced in 
293T cells and used to infect target Hela cells stably expressing ACE2 in the 
presence of serial dilutions of indicated monoclonal antibodies. Data are 
means of technical replicates with error bars representing SD. Data are 
representative of at least two independent experiments. RBD: receptor 
binding domain. B. Classes of RBD binding antibodies and fold changes for 
Spike mutations D796H or ΔH69/V70 are indicated based Bouwer et al. 
Clusters II, V contain only non-neutralising mAbs, smaller neutralising mAb 





























Extended Data Fig. 9 | Location of Spike mutations ΔH69/Y70 and D796H. 
A. The SARS-CoV-2 spike trimer (PDB ID: 6xr8) with two protomers represented 
as surfaces and one protomer represented as a ribbon. The NTD is coloured in 
light blue, the RBD in light pink, the fusion peptide in dark pink, the HR1 domain 
in yellow, the CH domain in pale green, and the CD domain in brown. The 
location of D796 and H69 are indicated by red spheres. The loop connecting 
D796 to the fusion peptide is coloured magenta to improve visibility. The 
double grey lines provide orientation relative to the membrane. B. A close-up 
of the region defined by the box around H69 in panel A. H69 is highlighted in 
yellow. Residues containing atoms that are within 6 Å of H69 are highlighted in 
cyan. C. A close-up of the region defined by the box around D796 in panel A. 
D796 is highlighted in yellow. Residues containing atoms that are within 6 Å of 
D796 are highlighted in cyan. Hydrogen bonds are indicated by dashed yellow 
lines. Hydrophobic residues in the vicinity of D796 have been labelled. Y707 is 
from the neighbouring protomer. D. Global prevalence of selected spike 
mutations detailed in this paper. All high coverage sequences were 
downloaded from the GISAID database on 6th January and aligned using MAFFT; 
as of this date there were 298254 sequences available. The global prevalence of 
each of the six spike mutations W64G, ΔH69/V70, Y200H, T240I, P330S and 
D796H were assessed by viewing the multiple sequence alignment in AliView, 
sorting by the column of interest, and counting the number of mutations.
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